Novartis AG v. Union of India ((2013) 6 SCC 1) is the most significant Supreme Court decision on pharmaceutical patents in India and a landmark in global intellectual property law. The Court upheld Section 3(d) of the Patents Act, 1970, which bars patents on new forms of known substances (such as salts, esters, polymorphs, and metabolites) unless they demonstrate "significantly enhanced therapeutic efficacy." By refusing a patent for the beta-crystalline form of imatinib mesylate (marketed as Glivec/Gleevec, a cancer drug), the Court established that incremental modifications to known drugs — a practice known as "evergreening" — are not patentable in India. This case is tested across CLAT, judiciary, and financial regulatory examinations.
Case snapshot
| Field | Details |
|---|---|
| Case name | Novartis AG v. Union of India |
| Citation | (2013) 6 SCC 1 |
| Court | Supreme Court of India |
| Bench | Aftab Alam, Ranjana Prakash Desai JJ. |
| Date of judgment | 1 April 2013 |
| Subject | Intellectual Property — Pharmaceutical Patents, Section 3(d), Evergreening |
| Key principle | New forms of known substances are not patentable unless they show significantly enhanced therapeutic efficacy; incremental innovation does not meet the inventive step threshold in India |
Facts of the case
Novartis AG, a Swiss pharmaceutical multinational, applied for a patent in India for the beta-crystalline form of imatinib mesylate — the active ingredient in its blockbuster cancer drug Glivec (marketed as Gleevec in the US). Imatinib itself was a known substance, and Novartis had obtained a patent for imatinib in free base form in several countries. The Indian patent application was for a specific crystalline salt form that Novartis claimed had improved physical properties — better bioavailability, thermodynamic stability, and flow properties.
The Madras Patent Office rejected the application under Section 3(d) of the Patents Act, 1970, holding that the beta-crystalline form of imatinib mesylate was a "new form of a known substance" that did not demonstrate "enhanced efficacy" as required by the provision. The Intellectual Property Appellate Board (IPAB) upheld the rejection on Section 3(d) grounds while overturning the novelty and inventive step objections. Novartis appealed to the Supreme Court, also challenging the constitutional validity of Section 3(d) as being arbitrary and TRIPS-incompatible.
Issues before the court
- Whether the beta-crystalline form of imatinib mesylate qualifies as a "new form of a known substance" under Section 3(d) of the Patents Act, 1970?
- What does "enhanced efficacy" mean in Section 3(d) — is it limited to therapeutic efficacy or does it include any improved physical property?
- Whether Section 3(d) is TRIPS-compliant and constitutionally valid?
- Whether Novartis's patent application satisfies the inventive step requirement under Section 2(1)(ja)?
What the court held
Beta-crystalline form is a "new form of a known substance" — The Court held that imatinib was a "known substance" and the beta-crystalline form of its mesylate salt was a "new form" of that known substance within the meaning of Section 3(d). The chemical identity of the therapeutic molecule had not changed — it was still imatinib. The crystalline form and salt selection were physical modifications that did not create a new substance.
"Efficacy" means therapeutic efficacy — The Court held that in the context of pharmaceutical products, "efficacy" in Section 3(d) means "therapeutic efficacy" — the ability of the drug to produce the desired therapeutic effect in patients. Improved physical properties such as better flow characteristics, thermodynamic stability, or storage convenience do not constitute "enhanced efficacy" unless they translate into improved therapeutic outcomes. Novartis had demonstrated improved bioavailability of the beta-crystalline form over imatinib free base, but the Court found that this did not necessarily mean enhanced therapeutic efficacy.
Section 3(d) is TRIPS-compliant — The Court declined to examine TRIPS compliance in detail, holding that Section 3(d) was an exercise of India's sovereign legislative power under the Patents Act, and that TRIPS Article 27 does not prevent member states from imposing additional patentability requirements. The Court observed that Section 3(d) operates within the TRIPS-permitted flexibilities that developing countries can use to balance patent protection with public health needs.
Inventive step not satisfied — The Court also held that the beta-crystalline form did not meet the inventive step requirement under Section 2(1)(ja), which requires that the invention must not be obvious to a person skilled in the art and must involve "technical advance" compared to existing knowledge or have "economic significance."
Key legal principles
Section 3(d) — the anti-evergreening provision
Section 3(d) provides that "the mere discovery of a new form of a known substance which does not result in the enhancement of the known efficacy of that substance" is not an invention. The Explanation clarifies that salts, esters, ethers, polymorphs, metabolites, pure form, particle size, isomers, mixtures of isomers, complexes, combinations, and other derivatives of a known substance are to be considered the same substance unless they differ significantly in properties with regard to efficacy.
The efficacy standard for pharmaceuticals
The Court established a two-step test for pharmaceutical patent applications under Section 3(d): (1) determine whether the claimed invention is a new form of a known substance, and (2) if yes, determine whether the new form demonstrates "significantly enhanced therapeutic efficacy" over the known substance. The applicant bears the burden of proving enhanced therapeutic efficacy through clinical or pharmacological data.
Balancing patents and public health
The judgment explicitly recognized India's position as the "pharmacy of the developing world" — Indian generic manufacturers supply affordable medicines to millions across the Global South. Section 3(d) was designed to prevent pharmaceutical companies from extending monopoly periods through minor modifications while ensuring that genuinely novel inventions continue to receive patent protection.
Significance
The Novartis judgment has global significance. It was celebrated by public health advocates and generic pharmaceutical manufacturers as a victory for affordable medicine, while the pharmaceutical industry argued it would discourage innovation in India. The decision affirmed India's unique approach to pharmaceutical patentability — more restrictive than the US or EU but TRIPS-compliant — and established Section 3(d) as a robust barrier against patent evergreening. The case has influenced patent examination practices in other developing countries and is cited in international discussions on access to medicines. Within India, it remains the definitive statement on the scope of Section 3(d) and the meaning of "enhanced efficacy."
Exam angle
MCQ: "Section 3(d) of the Patents Act, 1970 was upheld by the Supreme Court in:" — Answer: Novartis AG v. Union of India (2013) 6 SCC 1. Distractors: Bayer v. Natco Pharma (compulsory licensing), Yahoo v. Akash Arora (domain names), Eastern Book Co. v. Modak (copyright).
Descriptive: "Critically analyse the Supreme Court's interpretation of Section 3(d) of the Patents Act, 1970, in the Novartis case. How does this provision balance patent protection with public health?" — Structure: (1) Section 3(d) text and purpose, (2) facts of the Novartis application, (3) "efficacy means therapeutic efficacy" holding, (4) TRIPS compatibility, (5) impact on generic pharmaceutical industry, (6) comparison with US/EU standards.
Key facts to memorize:
- Drug: Imatinib mesylate (Glivec/Gleevec) — cancer drug
- Section 3(d): New form of known substance not patentable unless enhanced efficacy
- "Efficacy" = therapeutic efficacy, not physical properties
- Burden of proof: On the applicant to demonstrate enhanced therapeutic efficacy
- TRIPS: Section 3(d) held TRIPS-compliant (within permitted flexibilities)
- Section 2(1)(ja): Inventive step requires technical advance or economic significance
- India's role: "Pharmacy of the developing world" — generic drug supplier
Follow-up cases and developments:
- Bayer Corp. v. Natco Pharma (2012) — India's first compulsory licence under Section 84, for sorafenib (kidney/liver cancer drug)
- F. Hoffmann-La Roche v. Cipla (2015) — patent infringement injunction standards
- Lee Pharma v. AstraZeneca (2017) — applied Section 3(d) to diabetes drug
Frequently asked questions
What is "evergreening" and why does India prohibit it?
Evergreening is the practice of obtaining multiple sequential patents on minor modifications of the same drug — new salt forms, polymorphs, combinations, formulations — to extend the effective monopoly period beyond the original 20-year patent term. Section 3(d) of the Patents Act, 1970, prevents this by requiring that new forms of known substances must demonstrate "significantly enhanced therapeutic efficacy" to be patentable. India prohibits evergreening because it delays the entry of affordable generic versions, which is particularly harmful in a country where most patients pay out-of-pocket for medicines.
Did Novartis lose the right to sell Glivec in India?
No. The Supreme Court denied a patent for the beta-crystalline form — it did not ban the drug. Novartis continued to sell Glivec in India, but without patent exclusivity. Generic manufacturers could legally produce and sell generic versions of imatinib mesylate at significantly lower prices. The price difference was dramatic: Novartis's Glivec was priced at approximately Rs. 1.2 lakh per month, while generic versions were available for Rs. 8,000-10,000 per month.
Is Section 3(d) unique to India or do other countries have similar provisions?
Section 3(d) is largely unique to India, though several developing countries have adopted or considered similar provisions. The Philippines, Argentina, and some countries in the Andean Community have introduced analogous restrictions. The US and EU do not have an equivalent provision — they grant patents on new forms if they satisfy the standard novelty, inventive step, and industrial applicability requirements. This makes India's patentability threshold for pharmaceuticals higher than most developed countries.
How does this case interact with compulsory licensing under Section 84?
Section 3(d) and compulsory licensing (Section 84) are separate but complementary mechanisms. Section 3(d) prevents patents on undeserving innovations at the grant stage. Section 84 allows the government to grant a compulsory licence on an existing patent if the patented product is not available at a reasonably affordable price, the reasonable requirements of the public are not satisfied, or the invention is not worked in India. Both mechanisms serve the public health objective but operate at different stages of the patent lifecycle.